

**Annual Report**  
**Division of Rheumatology**  
**Department of Medicine - Jewish General Hospital**  
**January 1 - December 31, 2014**

**SUMMARY**

**1. Research and publications:**

Dr. Baron's primary research interest is scleroderma. Dr. Baron has established the Canadian Scleroderma Research Group (CSRG) and the McGill Early Arthritis Registry that has performed research on recent onset inflammatory arthritis. He has also created CANCoRC, the Canadian Consortium of Rheumatology Cohorts, in an attempt to strengthen Canadian rheumatology research by seeking common funding and identifying commonalities across rheumatic disease research teams.

Most recently he established the International Systemic Sclerosis Inception Cohort (INSYNC) to study specifically of recent onset cases of Scleroderma. This involves participation from many countries.

Dr. Baron's research has focused on ways of measuring disease activity and damage in scleroderma, as well as on aspects of nutritional deficiencies caused by the disease. In addition, he has brought in several labs to work with the biospecimens he has collected. They are working on multiple aspects of the disease, including the vascular abnormalities and control of fibroblast function.

He has also played an important role in Canada's rheumatic disease research community by creating the concept of the Systemic Autoimmune Rheumatic Diseases (SARDs) as a group that deserves attention as a whole rather than just individually.

Dr Hudson pursues research in systemic autoimmune rheumatic diseases. In particular, she is a principal investigator in the Canadian Scleroderma Research Group (CSRG), a pan-Canadian cohort of over 1500 systemic sclerosis patients followed annually since 2004. She has done primarily outcomes research on this national dataset. In addition, given the rarity of the disease at hand, she has also established several international collaborations with leading scleroderma experts worldwide (International Scleroderma Renal Crisis Survey, Tri-nation (Canada, Houston, Australia) Scleroderma Cohort (undertaken to study the clinical correlates of some of the less frequent autoantibodies found in this disease), and International Systemic Sclerosis Inception Cohort (INSYNC)).

Dr Hudson is also the Director of the Canadian Inflammatory Myopathy Study (CIMS). Funded by a CFI grant awarded in 2010, we developed a study protocol to prospectively follow an incident cohort of patients with inflammatory myopathies. The database has been created, we have begun to recruit at 2 sites (McGill University and Centre Hospitalier de l'Université Laval) and a meeting to launch the national cohort took place May 16, 2014. More than 50 participants from 12 sites across Canada will attend. We

aim to recruit approximately 100 incident cases per year over the next 3 years, making this a unique resource worldwide.

Finally, after doing outcomes research for several years, Dr Hudson has now decided to also undertake translational research aimed at studying the etiopathogenesis of systemic autoimmune rheumatic diseases (SARDs). She has developed collaborations with a number of other scientists, including geneticists and environmental health experts, and has established the Canadian Network for SysTemic Autoimmune rheumatic diseases (CAN-STAR). The objective of this multi-disciplinary, cross-pillar, cross-disease network is to define the epigenetic signatures of SARDs, to investigate the contribution of air pollution to epigenetic abnormalities and to translate new findings into relevant disease biomarkers and targets for future intervention.

Dr Hudson has been appointed to the position of JGH Associate Director of Clinical Research

## **2. Teaching and learning (undergraduate and graduate):**

The division continues to participate in undergraduate and post-graduate medical education. Dr Hudson is a tutor in the Basis of Medicine for medical students. She also supervises a number of undergraduate and medical students, as well as internal medicine residents, rheumatology fellows and post-graduate students.

Dr. Berskon has developed and introduced seminar teaching series for rheumatology fellows, GIM fellows, and endocrinology fellows in osteoporosis since 2013.

The members of the division spent a total of 2 weeks as attending on the medial wards.

## **3. Involvement in the community:**

Dr Baron is on the JGH policy committee.

Dr. Hudson is on the LDI/JGH Clipp grant review committee.

## **4. Partnerships:**

The rheumatology research group has instituted the development of a new international research organization called The International Systemic Sclerosis Inception Cohort (InSync) with the aim of closely following the first few years of illness in patients with scleroderma from many different countries to develop a large enough cohort for important research. InSync includes researchers from Canada, United States, Germany, Holland, Sweden, Australia and Spain.

Dr. Baron has established the Canadian Consortium of Rheumatology Research Cohorts (CANCoRC) which is a group of about 20 cohorts that work on cross-group efficiencies

and look at biospecimen SOPs, biospecimen tracking systems, ethics submissions and consent forms, cross disease data harmonization, and sharing web page resources.

As described above, Dr. Hudson participates in research on epigenetics of rheumatic diseases with a group at McGill University (CAN\_STAR) and has established a new national cohort in inflammatory myopathies (CIMS).

The Division runs an osteoporosis clinic in partnership with endocrinology. It has a once/month clinic for rheumatic disease with lung disease and/or pulmonary hypertension. Scleroderma patients are seen once per week for collection of data for the Canadian Scleroderma Research group.

**5. Milestones:**

There were no changes in staffing in 2014.

**6. Honours, awards, and prizes:** None to report

**7. Fundraising:**

The division has received \$130,000 in donation for research purposes.

**SECTION I - DIVISION STATUS UPDATE**

**1. Mission and objectives of the Division**

The Division strives to provide high level clinical care, education and research.

**2. A nominative list of academic staff, their academic rank**

Murray Baron, MD: Professor of Medicine  
Marie Hudson, MD: Assistant Professor  
Genevieve Gyger, MD: Attending Physician  
Laeora Berkson, MD: Associate Professor of Medicine  
Sabrina Fallavollita, MD: Assistant Professor

**SECTION II - GRANTS, PUBLICATIONS, AND SERVICE OUTSIDE OF MCGILL**

**1. Grants and awards received**

Baron, Murray and Hudson Marie

- 2012-2017 Emerging Team: The Scleroderma Patient-centered Intervention Network (Emerging Team Grant: Rare Diseases - \$1,500,000; PI Thombs); Canadian Institutes of Health Research (CIHR)
- 2010-2014 McGill Systemic Autoimmune Rheumatic Diseases (SARD) Project, CFI, PI Baron, \$790,000
- Hudson, Marie
- 2012-2016 Multidimensional Epigenomics Mapping Centre (EMC) at McGill, CIHR, Co-PI \$5,665,000
- 2013-2014 Canadian Inflammatory Myopathy Study Networking Meeting, the Arthritis Society, PI Hudson, \$10,000
- 2013-2014 CAN-STAR – Canadian Network for Systemic Autoimmune Rheumatic Diseases (LOI), CIHR , PI Hudson, \$18,975
- 2013-2014 ImmunoSeq: novel immunogenetic discovery tool and its translation to personalized medicine in Finnish and Canadian partnership (LOI), CIHR, Co-PI, \$20,000
- 2012-2014 Searching for identity in the dark: the experiences of women living with a rare and unpredictable disease (Insight Development Grants - \$75,000; PI Thombs); Sciences Research Council (SSRC)

**Salary awards:**

Hudson, Marie :

- 2012-2015: Bourse de Chercheur-clinicien Junior 2, FRSQ  
 2012-2017: The Arthritis Society Investigator Salary Award (declined)

**2. Scholarly works published in the 2014 calendar year:**

**Baron, Murray**

1: Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schioppa E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. *Semin Arthritis Rheum.* 2015 Jun;44(6):680-6. doi: 10.1016/j.semarthrit.2014.11.006. Epub 2014 Nov 28. PubMed PMID: 25578738; PubMed Central PMCID: PMC4447614.

- 2: Baron M, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis. *Rheumatology (Oxford)*. 2015 Apr;54(4):692-6. doi: 10.1093/rheumatology/keu396. Epub 2014 Oct 6. PubMed PMID: 25288781; PubMed Central PMCID: PMC4372678.
- 3: Diab S, Dostrovsky N, Hudson M, Tatibouet S, Fritzler MJ, Baron M, Khalidi N; Canadian Scleroderma Research Group. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. *J Rheumatol*. 2014 Nov;41(11):2179-85. doi: 10.3899/jrheum.140236. Epub 2014 Oct 1. PubMed PMID: 25274885.
- 4: Massie C, Hudson M, Tatibouet S, Steele R, Huynh T, Fritzler MJ, Baron M, Pineau CA; Canadian Scleroderma Research Group (CSRG). Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: a multicenter study of 689 patients. *Semin Arthritis Rheum*. 2014 Dec;44(3):338-44. doi: 10.1016/j.semarthrit.2014.07.001. Epub 2014 Jul 15. PubMed PMID: 25128430.
- 5: D'Aoust J, Hudson M, Baron M, Mahler M, Fritzler MJ. Reply: To PMID 24577935. *Arthritis Rheumatol*. 2014 Nov;66(11):3249-50. doi: 10.1002/art.38801. PubMed PMID: 25077459.
- 6: Delisle VC, Kwakkenbos L, Hudson M, Baron M, Thombs BD; Canadian Scleroderma Research Group. An assessment of the measurement equivalence of English and French versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in systemic sclerosis. *PLoS One*. 2014 Jul 18;9(7):e102897. doi: 10.1371/journal.pone.0102897. eCollection 2014. PubMed PMID: 25036894; PubMed Central PMCID: PMC4103860.
- 7: Mahler M, Satoh M, Hudson M, Baron M, Chan JY, Chan EK, Wick J, Fritzler MJ; Canadian Scleroderma Research Group. Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. *J Rheumatol*. 2014 Jul;41(7):1334-43. doi: 10.3899/jrheum.131450. Epub 2014 Jun 15. PubMed PMID: 24931955.
- 8: Arts MR, Baron M, Chokr N, Fritzler MJ; Canadian Scleroderma Research Group (CSRG), Servant MJ. Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor. *PLoS One*. 2014 Jun 13;9(6):e100035. doi: 10.1371/journal.pone.0100035. eCollection 2014. PubMed PMID: 24927197; PubMed Central PMCID: PMC4057313.
- 9: Johnson SR, Naden RP, Fransen J, van den Hoogen F, Pope JE, Baron M, Tyndall A, Matucci-Cerinic M, Denton CP, Distler O, Gabrielli A, van Laar JM, Mayes M,

Steen V, Seibold JR, Clements P, Medsger TA Jr, Carreira PE, Riemekasten G, Chung L, Fessler BJ, Merkel PA, Silver R, Varga J, Allanore Y, Mueller-Ladner U, Vonk MC, Walker UA, Cappelli S, Khanna D. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. *J Clin Epidemiol.* 2014 Jun;67(6):706-14. doi: 10.1016/j.jclinepi.2013.12.009. Epub 2014 Apr 8. PubMed PMID: 24721558; PubMed Central PMCID: PMC4134523.

10: Kwakkenbos L, Willems LM, Baron M, Hudson M, Cella D, van den Ende CH, Thombs BD; Canadian Scleroderma Research Group. The comparability of English, French and Dutch scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): an assessment of differential item functioning in patients with systemic sclerosis. *PLoS One.* 2014 Mar 17;9(3):e91979. doi: 10.1371/journal.pone.0091979. eCollection 2014. PubMed PMID: 24638101; PubMed Central PMCID: PMC3956818.

11: Rockwood MR, MacDonald E, Sutton E, Rockwood K, Baron M; Canadian Scleroderma Research Group. Frailty index to measure health status in people with systemic sclerosis. *J Rheumatol.* 2014 Apr;41(4):698-705. doi: 10.3899/jrheum.130182. Epub 2014 Mar 1. PubMed PMID: 24584923.

12: D'Aoust J, Hudson M, Tatibouet S, Wick J; Canadian Scleroderma Research Group, Mahler M, Baron M, Fritzler MJ. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. *Arthritis Rheumatol.* 2014 Jun;66(6):1608-15. doi: 10.1002/art.38428. PubMed PMID: 24577935.

13: Luck Y, Baron M, Bardakjian S, Berkson L, Buchignani M, Fallavolita S, Giac F, Gyger G, Tatibouet S, Hudson M. The role of rheumatologists vis-à-vis assessment of traditional cardiovascular risk factors in rheumatoid arthritis. *Clin Rheumatol.* 2014 Jun;33(6):769-74. doi: 10.1007/s10067-014-2522-5. Epub 2014 Feb 15. PubMed PMID: 24526251.

14: Baron M, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, Masseto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. *Rheumatology (Oxford).* 2014 Aug;53(8):1386-94. doi: 10.1093/rheumatology/ket441. Epub 2014 Jan 24. PubMed PMID: 24464709; PubMed Central PMCID: PMC4103515.

15: Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D; International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. *Semin Arthritis Rheum.* 2014 Apr;43(5):666-72. doi: 10.1016/j.semarthrit.2013.09.008. Epub 2013 Oct 7. PubMed PMID: 24176729.

16: Delisle VC, Hudson M, Baron M, Thombs BD, And The Canadian Scleroderma Research Group A. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry. *Clin Exp Rheumatol*. 2014 Nov-Dec;32(6 Suppl 86):S-10-4. Epub 2013 Oct 11. PubMed PMID: 24144459.

17: Hudson M, Satoh M, Chan JY, Tatibouet S, Mehra S, Baron M, Fritzler M; Canadian Scleroderma Research Group. Prevalence and clinical profiles of 'autoantibody-negative' systemic sclerosis subjects. *Clin Exp Rheumatol*. 2014 Nov-Dec;32(6 Suppl 86):S-127-32. Epub 2013 Oct 21. PubMed PMID: 24144389.

18: Thombs BD, Razykov I, Hudson M, Baron M. Reply: To PMID 23203723. *Arthritis Care Res (Hoboken)*. 2014 Mar;66(3):497-8. doi: 10.1002/acr.22188. PubMed PMID: 24115746.

### **Hudson, Marie**

1: Salazar GA, Assassi S, Wigley F, Hummers L, Varga J, Hinchcliff M, Khanna D, Schioppa E, Phillips K, Furst DE, Steen V, Baron M, Hudson M, Taillefer SS, Pope J, Jones N, Docherty P, Khalidi NA, Robinson D, Simms RW, Silver RM, Frech TM, Fessler BJ, Molitor JA, Fritzler MJ, Segal BM, Al-Kassab F, Perry M, Yang J, Zamanian S, Reveille JD, Arnett FC, Pedroza C, Mayes MD. Antinuclear antibody-negative systemic sclerosis. *Semin Arthritis Rheum*. 2015 Jun;44(6):680-6. doi: 10.1016/j.semarthrit.2014.11.006. Epub 2014 Nov 28. PubMed PMID: 25578738; PubMed Central PMCID: PMC4447614.

2: Baron M, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis. *Rheumatology (Oxford)*. 2015 Apr;54(4):692-6. doi: 10.1093/rheumatology/keu396. Epub 2014 Oct 6. PubMed PMID: 25288781; PubMed Central PMCID: PMC4372678.

3: Diab S, Dostrovsky N, Hudson M, Tatibouet S, Fritzler MJ, Baron M, Khalidi N; Canadian Scleroderma Research Group. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. *J Rheumatol*. 2014 Nov;41(11):2179-85. doi: 10.3899/jrheum.140236. Epub 2014 Oct 1. PubMed PMID: 25274885.

4: Massie C, Hudson M, Tatibouet S, Steele R, Huynh T, Fritzler MJ, Baron M, Pineau CA; Canadian Scleroderma Research Group (CSRG). Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: a multicenter study of 689 patients. *Semin Arthritis Rheum*. 2014 Dec;44(3):338-44. doi: 10.1016/j.semarthrit.2014.07.001. Epub 2014 Jul 15. PubMed PMID: 25128430.

- 5: D'Aoust J, Hudson M, Baron M, Mahler M, Fritzler MJ. Reply: To PMID 24577935. *Arthritis Rheumatol.* 2014 Nov;66(11):3249-50. doi: 10.1002/art.38801. PubMed PMID: 25077459.
- 6: Delisle VC, Kwakkenbos L, Hudson M, Baron M, Thombs BD; Canadian Scleroderma Research Group. An assessment of the measurement equivalence of English and French versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in systemic sclerosis. *PLoS One.* 2014 Jul 18;9(7):e102897. doi: 10.1371/journal.pone.0102897. eCollection 2014. PubMed PMID: 25036894; PubMed Central PMCID: PMC4103860.
- 7: Mahler M, Satoh M, Hudson M, Baron M, Chan JY, Chan EK, Wick J, Fritzler MJ; Canadian Scleroderma Research Group. Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. *J Rheumatol.* 2014 Jul;41(7):1334-43. doi: 10.3899/jrheum.131450. Epub 2014 Jun 15. PubMed PMID: 24931955.
- 8: Kwakkenbos L, Willems LM, Baron M, Hudson M, Cella D, van den Ende CH, Thombs BD; Canadian Scleroderma Research Group. The comparability of English, French and Dutch scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): an assessment of differential item functioning in patients with systemic sclerosis. *PLoS One.* 2014 Mar 17;9(3):e91979. doi: 10.1371/journal.pone.0091979. eCollection 2014. PubMed PMID: 24638101; PubMed Central PMCID: PMC3956818.
- 9: Broten L, Aviña-Zubieta JA, Lacaille D, Joseph L, Hanly JG, Lix L, O'Donnell S, Barnabe C, Fortin PR, Hudson M, Jean S, Peschken C, Edworthy SM, Svenson L, Pineau CA, Clarke AE, Smith M, Bélisle P, Badley EM, Bergeron L, Bernatsky S. Systemic autoimmune rheumatic disease prevalence in Canada: updated analyses across 7 provinces. *J Rheumatol.* 2014 Apr;41(4):673-9. doi: 10.3899/jrheum.130667. Epub 2014 Mar 1. PubMed PMID: 24584928.
- 10: D'Aoust J, Hudson M, Tatibouet S, Wick J; Canadian Scleroderma Research Group, Mahler M, Baron M, Fritzler MJ. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. *Arthritis Rheumatol.* 2014 Jun;66(6):1608-15. doi: 10.1002/art.38428. PubMed PMID: 24577935.
- 11: Luck Y, Baron M, Bardakjian S, Berkson L, Buchignani M, Fallavolita S, Giac F, Gyger G, Tatibouet S, Hudson M. The role of rheumatologists vis-à-vis assessment of traditional cardiovascular risk factors in rheumatoid arthritis. *Clin Rheumatol.* 2014 Jun;33(6):769-74. doi: 10.1007/s10067-014-2522-5. Epub 2014 Feb 15. PubMed PMID: 24526251.
- 12: Baron M, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh



T, Pope J, Fontaine A, Masseto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. *Rheumatology (Oxford)*. 2014 Aug;53(8):1386-94. doi: 10.1093/rheumatology/ket441. Epub 2014 Jan 24. PubMed PMID: 24464709; PubMed Central PMCID: PMC4103515.

13: Hudson M, Fritzler MJ. Diagnostic criteria of systemic sclerosis. *J Autoimmun*. 2014 Feb-Mar;48-49:38-41. doi: 10.1016/j.jaut.2013.11.004. Epub 2014 Jan 22. Review. PubMed PMID: 24461384.

14: Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D; International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. *Semin Arthritis Rheum*. 2014 Apr;43(5):666-72. doi: 10.1016/j.semarthrit.2013.09.008. Epub 2013 Oct 7. PubMed PMID: 24176729.

15: Delisle VC, Hudson M, Baron M, Thombs BD, And The Canadian Scleroderma Research Group A. Sex and time to diagnosis in systemic sclerosis: an updated analysis of 1,129 patients from the Canadian scleroderma research group registry. *Clin Exp Rheumatol*. 2014 Nov-Dec;32(6 Suppl 86):S-10-4. Epub 2013 Oct 11. PubMed PMID: 24144459.

16: Hudson M, Satoh M, Chan JY, Tatibouet S, Mehra S, Baron M, Fritzler M; Canadian Scleroderma Research Group. Prevalence and clinical profiles of 'autoantibody-negative' systemic sclerosis subjects. *Clin Exp Rheumatol*. 2014 Nov-Dec;32(6 Suppl 86):S-127-32. Epub 2013 Oct 21. PubMed PMID: 24144389.

17: Thombs BD, Razykov I, Hudson M, Baron M. Reply: To PMID 23203723. *Arthritis Care Res (Hoboken)*. 2014 Mar;66(3):497-8. doi: 10.1002/acr.22188. PubMed PMID: 24115746.

### **Genevieve Gyger:**

1: Baron M, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, Masetto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis. *Rheumatology (Oxford)*. 2015 Apr;54(4):692-6. doi: 10.1093/rheumatology/keu396. Epub 2014 Oct 6. PubMed PMID: 25288781; PubMed Central PMCID: PMC4372678.

2: Luck Y, Baron M, Bardakjian S, Berkson L, Buchignani M, Fallavolita S, Giac F, Gyger G, Tatibouet S, Hudson M. The role of rheumatologists vis-à-vis assessment of traditional cardiovascular risk factors in rheumatoid arthritis. *Clin Rheumatol*. 2014

Jun;33(6):769-74. doi: 10.1007/s10067-014-2522-5. Epub 2014 Feb 15. PubMed PMID: 24526251.

3: Baron M, Hudson M, Tatibouet S, Steele R, Lo E, Gravel S, Gyger G, El Sayegh T, Pope J, Fontaine A, Masseto A, Matthews D, Sutton E, Thie N, Jones N, Copete M, Kolbinson D, Markland J, Nogueira-Filho G, Robinson D, Gornitsky M. The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. *Rheumatology (Oxford)*. 2014 Aug;53(8):1386-94. doi: 10.1093/rheumatology/ket441. Epub 2014 Jan 24. PubMed PMID: 24464709; PubMed Central PMCID: PMC4103515.

### **Laeora Berkson**

1: Luck Y, Baron M, Bardakjian S, Berkson L, Buchignani M, Fallavolita S, Giac F, Gyger G, Tatibouet S, Hudson M. The role of rheumatologists vis-à-vis assessment of traditional cardiovascular risk factors in rheumatoid arthritis. *Clin Rheumatol*. 2014 Jun;33(6):769-74. doi: 10.1007/s10067-014-2522-5. Epub 2014 Feb 15. PubMed PMID: 24526251.

### **3. Academic and community engagement service outside of McGill by individual members of the unit**

Dr. M. Hudson is a spokesperson for The Arthritis Society and serves as a medical advisor to the Arthritis West Island Self-Help Association (AWISH). Dr. L. Berkson serves as consultant rheumatologist for McGill RUIS, Abitibi, QC

## **SECTION III - CONFIDENTIAL INFORMATION**

### **1. Consulting activities: None**

Submitted by:

Murray Baron, MD  
Chief, Division of Rheumatology